Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Development of an immune-armed therapeutic adenoviral platform for pediatric brain tumors

Project description

Oncolytic virus therapy for aggressive paediatric brain tumours

Oncolytic viruses are engineered to selectively infect and kill cancer cells while triggering an immune response against the tumour. They have emerged as a promising cancer treatment. The ERC-funded POPCORN project aims to develop a next-generation oncolytic virus therapy for diffuse midline glioma, one of the most malignant paediatric brain tumours with a median survival of less than 14 months. Researchers propose the engineering of oncolytic adenoviruses that deliver immunomodulatory single-domain antibodies directly to the tumour. By augmenting the immunostimulating function of oncolytic viruses, the study has the potential to provide a revolutionary treatment for difficult-to-treat childhood brain tumours.

Objective

Diffuse Midline Gliomas (DMGs) are the most aggressive pediatric brain tumors in desperate need of curative treatment. The median life expectancy of these children remains below 14 months after diagnosis, and nearly none survive beyond the second year. Similarly, for other high-risk pediatric brain tumors, there is hardly any option after recurrence, and long-term survivors are faced with life-long sequelae that impact their quality of life. In this scenario, there is an urgent need for innovative, efficacious, and safe therapies for these patients. Oncolytic viruses are promising anticancer biotherapeutic agents that offer a unique combination of safety profile, direct antineoplastic activity, and the induction of anti-tumor immune responses. Recently, a Phase I clinical trial showed that combining the oncolytic adenovirus Delta-24-RGD and radiotherapy is non-toxic and results in anti-tumor responses and prolonged median overall survival (17.8 months) in patients. However, results are still insufficient to be curative due to counteracting mechanisms intrinsic to the tumor microenvironment and also triggered by the virus that eventually exceeds its immunostimulatory properties. The proposed technology, termed “POPCORN”', is an oncolytic-based platform capable of expressing immunomodulatory single-domain antibodies directed to intrinsic targets in these tumors. We will develop the POPCORN Proof of Concept using a state-of-the-art experimental approach and validate its safety and efficacy in vitro and relevant in vivo DMG models. We will also perform IND-enabling studies and apply for PUMA/PRIME designation. Additionally, we will work on the IPR strategy, and a value proposition to develop and commercialize the POPCORN platform will be generated. We envision the POPCORN platform becoming a game changer in treating DMGs, providing a one-of-a-kind tool for eliminating these aggressive tumors that could be extensive to other difficult-to-treat pediatric brain tumors.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

UNIVERSIDAD DE NAVARRA
Net EU contribution
€ 150 000,00
Address
CAMPUS UNIVERSITARIO EDIFICIO CENTRAL
31080 Pamplona
Spain
Region
Noreste Comunidad Foral de Navarra Navarra
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)